Copyright © 2013 Knight Sac Media. All rights reserved.http://www.siliconinvestor.com/subject.aspx?subjectid=51033Hepatitis is a worldwide epidemic, and a lot of companies are working on better treatments. This is the most helpful link I've found for an overview for the U.S. (in case it expires, I've taken the liberty of excerpting a bit): hepnet.com  >>Chronic Viral Hepatitis in the United States Norah Ter...http://www.siliconinvestor.com/images/Logo380x132.pnghttp://www.siliconinvestor.com/subject.aspx?subjectid=5103338013210DewDiligence_on_SIPlease vote in new iHub survey on competition for hegemony in all-oral HCV: investorshub.advfn.com  Thanks in advance.http://www.siliconinvestor.com/readmsg.aspx?msgid=2854484311/13/2012 1:17:55 PMDewDiligence_on_SIABT is running *7* phase-3 trials in genotype-1 HCV: investorshub.advfn.com  investorshub.advfn.com http://www.siliconinvestor.com/readmsg.aspx?msgid=2854329011/12/2012 7:57:44 PMDewDiligence_on_SIhttp://www.siliconinvestor.com/readmsg.aspx?msgid=2851289710/31/2012 7:59:07 PMDewDiligence_on_SIABT’s astonishing results in HCV (abstract posted for AASLD conference): investorshub.advfn.com  investorshub.advfn.com  investorshub.advfn.com  Please see the replies to the above posts for additional commentary.http://www.siliconinvestor.com/readmsg.aspx?msgid=2847511610/15/2012 7:19:48 PMDewDiligence_on_SIhttp://www.siliconinvestor.com/readmsg.aspx?msgid=282978697/27/2012 6:29:40 PMDewDiligence_on_SIhttp://www.siliconinvestor.com/readmsg.aspx?msgid=280627334/5/2012 11:32:00 AMDewDiligence_on_SIhttp://www.siliconinvestor.com/readmsg.aspx?msgid=280627284/5/2012 11:30:47 AMksuaveWhat Canadian company might this article about a possible breakthrough be about? labnews.co.uk http://www.siliconinvestor.com/readmsg.aspx?msgid=280622154/5/2012 8:25:20 AMtuckhttp://www.siliconinvestor.com/readmsg.aspx?msgid=280554114/2/2012 2:52:12 PMtnsafAnother HCV target if the current ones are not sufficient for an all-oral treatment Structure of a hepatitis C virus RNA domain in complex with a translation inhibitor reveals a binding mode reminiscent of riboswitches Sergey M. Dibrov a, Kejia D...http://www.siliconinvestor.com/readmsg.aspx?msgid=280281663/21/2012 11:37:23 PMidos Basic research Potential new use for Zetia: blocks HCV entry in vitro nature.com http://www.siliconinvestor.com/readmsg.aspx?msgid=278695431/9/2012 11:29:11 AMDewDiligence_on_SINot a serious worry, IMO. An approved vaccine for HCV is still pretty far off and it won't help those who are already infected, which is the vast majority of the HCV market. Regards, Dewhttp://www.siliconinvestor.com/readmsg.aspx?msgid=278610511/4/2012 7:25:25 PMChris08Gilead can hope that the VRUS drug it paid so much for can be exploited to the full before any vaccine comes onto the market. news.yahoo.com http://www.siliconinvestor.com/readmsg.aspx?msgid=278604221/4/2012 3:17:28 PMksuaveAethlon Medical Announces Data Supported Strategy To Increase Hepatitis-C (HCV) Cure Rates Posted on January 4, 2012by makibazym Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced clinical data that supports the advancement of the Aethlon Hemopurifier(R) as an adjunct therapy to increase Hepatitis-C (HCV...http://www.siliconinvestor.com/readmsg.aspx?msgid=278601221/4/2012 1:59:24 PMDewDiligence_on_SIBMY/JNJ plan phase-2 trial of BMS-790052 + TMC435 in genotype-1 patients: investorshub.advfn.com http://www.siliconinvestor.com/readmsg.aspx?msgid=2779989912/2/2011 8:38:00 AM